Phibro Animal Health Corporation $PAHC Shares Purchased by JPMorgan Chase & Co.

JPMorgan Chase & Co. raised its stake in Phibro Animal Health Corporation (NASDAQ:PAHC) by 1,730.9% during the third quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund owned 238,115 shares of the company’s stock after purchasing an additional 225,110 shares during the quarter. JPMorgan Chase & Co.’s holdings in Phibro Animal Health were worth $9,634,000 at the end of the most recent quarter.

Several other institutional investors also recently made changes to their positions in the stock. Balboa Wealth Partners purchased a new position in shares of Phibro Animal Health in the 3rd quarter worth $216,000. Public Sector Pension Investment Board grew its position in Phibro Animal Health by 14.7% during the third quarter. Public Sector Pension Investment Board now owns 79,478 shares of the company’s stock valued at $3,216,000 after acquiring an additional 10,184 shares during the period. Cornerstone Investment Partners LLC acquired a new stake in Phibro Animal Health during the third quarter worth about $209,000. Navellier & Associates Inc. raised its holdings in shares of Phibro Animal Health by 17.9% in the 3rd quarter. Navellier & Associates Inc. now owns 51,626 shares of the company’s stock worth $2,089,000 after purchasing an additional 7,855 shares during the period. Finally, Prospera Financial Services Inc raised its holdings in shares of Phibro Animal Health by 21.7% in the 3rd quarter. Prospera Financial Services Inc now owns 24,237 shares of the company’s stock worth $981,000 after purchasing an additional 4,327 shares during the period. 99.34% of the stock is owned by hedge funds and other institutional investors.

Insider Buying and Selling at Phibro Animal Health

In other news, CEO Jack Bendheim sold 7,040 shares of Phibro Animal Health stock in a transaction dated Thursday, February 26th. The stock was sold at an average price of $53.73, for a total transaction of $378,259.20. Following the sale, the chief executive officer directly owned 1,480 shares of the company’s stock, valued at approximately $79,520.40. The trade was a 82.63% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Insiders sold 299,200 shares of company stock worth $14,249,723 in the last three months. 50.13% of the stock is owned by company insiders.

Phibro Animal Health Trading Down 3.4%

PAHC opened at $47.92 on Friday. The firm’s 50 day moving average is $45.11 and its 200-day moving average is $41.56. Phibro Animal Health Corporation has a 52-week low of $16.16 and a 52-week high of $56.30. The company has a quick ratio of 1.22, a current ratio of 3.05 and a debt-to-equity ratio of 2.14. The firm has a market capitalization of $1.94 billion, a P/E ratio of 21.30, a P/E/G ratio of 0.76 and a beta of 0.74.

Phibro Animal Health (NASDAQ:PAHC) last announced its earnings results on Wednesday, February 4th. The company reported $0.87 earnings per share for the quarter, beating the consensus estimate of $0.69 by $0.18. Phibro Animal Health had a net margin of 6.29% and a return on equity of 38.28%. The business had revenue of $373.91 million during the quarter, compared to the consensus estimate of $355.64 million. Phibro Animal Health has set its FY 2026 guidance at 2.930-3.100 EPS. Analysts expect that Phibro Animal Health Corporation will post 1.95 EPS for the current fiscal year.

Phibro Animal Health Dividend Announcement

The firm also recently announced a quarterly dividend, which will be paid on Wednesday, March 25th. Stockholders of record on Wednesday, March 4th will be paid a dividend of $0.12 per share. The ex-dividend date is Wednesday, March 4th. This represents a $0.48 annualized dividend and a dividend yield of 1.0%. Phibro Animal Health’s dividend payout ratio (DPR) is currently 21.33%.

Analyst Ratings Changes

PAHC has been the subject of a number of research reports. Zacks Research cut Phibro Animal Health from a “strong-buy” rating to a “hold” rating in a report on Monday, February 9th. Weiss Ratings reiterated a “buy (b-)” rating on shares of Phibro Animal Health in a research note on Monday, December 29th. JPMorgan Chase & Co. raised their target price on shares of Phibro Animal Health from $45.00 to $50.00 and gave the company an “overweight” rating in a research note on Friday, November 7th. Finally, Morgan Stanley set a $49.00 price target on shares of Phibro Animal Health in a research report on Friday, February 6th. Two investment analysts have rated the stock with a Buy rating, three have assigned a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat.com, Phibro Animal Health has an average rating of “Hold” and a consensus price target of $37.50.

Phibro Animal Health Profile

Phibro Animal Health Corporation (NASDAQ: PAHC) is a diversified global animal health and mineral nutrition company headquartered in Teaneck, New Jersey. The company develops, manufactures and markets a broad range of pharmaceutical, mineral nutrition and performance products designed to support the health and productivity of livestock, companion animals and aquaculture species. Phibro’s portfolio includes vaccines, anti-infective therapies, coccidiostats, disinfectants, premix minerals and specialty feed additives aimed at enhancing growth, immunity and overall animal well-being.

The company operates through three principal business segments: Animal Health, Mineral Nutrition and Performance Products.